✦ LIBER ✦

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study

✍ Scribed by Antonio Rozzi; Chiara Nardoni; Michela Corona; Maria Rosa Restuccia; Alessandra Fabi; Emilio Bria; Giuseppe Minniti; Gaetano Lanzetta

Publisher: Springer-Verlag
Year: 2010
Tongue: English
Weight: 114 KB
Volume: 19
Category: Article
ISSN: 0941-4355
DOI: 10.1007/s00520-010-0893-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of olanzapine, dexameth

A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

✍ Rudolph M. Navari; Lawrence H. Einhorn; Patrick J. Loehrer; Steven D. Passik; Ja 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 165 KB

Daily palonosetron is superior to ondans

Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia

✍ Gloria N. Mattiuzzi; Jorge E. Cortes; Deborah A. Blamble; B. Nebiyou Bekele; Lia 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB 👁 1 views

A phase II trial of olanzapine for the p

A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study

✍ Rudolph M. Navari; Lawrence H. Einhorn; Steven D. Passik; Patrick J. Loehrer; Cy 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 97 KB

Single-dose palonosetron for prevention

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

✍ Nicola Di Renzo; Antonella Montanini; Donato Mannina; Alessandra Dondi; Stefania 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 141 KB

Palonosetron in combination with 1-day v

Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial

✍ Luigi Celio; Sergio Frustaci; Angela Denaro; Angela Buonadonna; Antonio Ardizzoi 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 185 KB

A phase I study of a new 5HT3-receptor a

A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting

✍ Geoffrey Falkson; Adriaan J. Zyl 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 370 KB

In a phase I study of BRL43694A, a 5HT3-receptor antagonist, a single dose of 40 micrograms/kg was given to 24 patients. All patients received cytostatic treatment expected to cause nausea and vomiting. During the first 24 h, 12 patients were completely protected from nausea and vomiting, 4 experien